Diet and tumor LKB1 expression interact to determine sensitivity to anti-neoplastic effects of metformin in vivo

Oncogene

Volumn 30, Issue 10, 2011, Pages 1174-1182

  Algire, C ^a   Amrein, L ^b   Bazile, M ^b   David, S ^b   Zakikhani, M ^b   Pollak, M ^a  

^a MCGILL UNIVERSITY   (Canada)

^b MCGILL UNIVERSITY   (Canada)

Author keywords

cancer; insulin; LKB1; metformin

Indexed keywords

ADENOSINE TRIPHOSPHATE; ADENYLATE KINASE; GLUCOSE; INSULIN RECEPTOR; METFORMIN; PROTEIN KINASE LKB1; SHORT HAIRPIN RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DIET; ENERGY CONSERVATION; GLUCOSE INTAKE; HYPERINSULINEMIA; INTRACELLULAR SIGNALING; LOSS OF FUNCTION MUTATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; DIET; DRUG RESISTANCE, NEOPLASM; GENES, TUMOR SUPPRESSOR; HYPERINSULINISM; HYPOGLYCEMIC AGENTS; MALE; METFORMIN; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; PROTEIN-SERINE-THREONINE KINASES; SIGNAL TRANSDUCTION; TRANSFECTION;

MUS;

EID: 79952538201     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.483     Document Type: Article

References (48)

1. Algire C, Amrein L, Zakikhani M, Panasci L, Pollak M. (2010). Metformin blocks the stimulative effect of a high energy diet on colon carcinoma growth in vivo and is associated with reduced expression of fatty acid acid synthase. Endocr Relat Cancer 17: 351-360.
2. Algire C, Zakikhani M, Blouin M-J, Shuai JH, Pollak M. (2008). Metformin attenuates the stimulatory effect of a high energy diet on in vivo H59 carcinoma growth. Endocr Relat Cancer 15: 833-839.
3. Blake DA, McLean NV. (1989). A colorimetric assay for the measurement of -glucose consumption by cultured cells. Anal Biochem 177: 156-160. (Pubitemid 19081738)
4. Bodmer M, Meier C, Krahenbuhl S, Jick SS, Meier CR, Meier CR. (2010). Long-term metformin use is associated with decreased risk of breast cancer. Diabetes Care 33: 1304-1308.
5. Buzzai M, Jones RG, Amaravadi RK, Lum JJ, DeBerardinis RJ, Zhao F et al. (2007). Systemic treatment with the antidiabetic drug metformin selectively impairs p53-deficient tumor cell growth. Cancer Res 67: 6745-6752. (Pubitemid 47105521)
6. Currie CJ, Poole CD, Gale EA. (2009). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes. Diabetologia 52: 1766-1777.
7. DeFronzo RA, Goodman AM. (1995). Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multi-center Metformin Study Group. N Engl J Med 333: 541-549.
8. Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N. (2007). Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res 67: 10804-10812. (Pubitemid 350145909)
9. Dykens JA, Jamieson J, Marroquin L, Nadanaciva S, Billis PA, Will Y. (2008). Biguanide-induced mitochondrial dysfunction yields increased lactate production and cytotoxicity of aerobically-poised HepG2 cells and human hepatocytes in vitro. Toxicol Appl Pharmacol 233: 203-210. (Pubitemid 50293339)
10. Engelman, Cantley. (2010). Chemoprevention meets glucose control. Can Prev Res 3: 1049-1052.
11. El Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. (2000). Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem 275: 223-228. (Pubitemid 30038975)
12. Evans JM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD. (2005). Metformin and reduced risk of cancer in diabetic patients. BMJ 330: 1304-1305. (Pubitemid 40813563)
13. Fantin VR, St Pierre J, Leder P. (2006). Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell 9: 425-434. (Pubitemid 43832190)
14. Foretz M, Hebrard S, Leclerc J, Zarrinpashneh E, Soty M, Mithieux G et al. (2010). Metformin inhibits hepatic gluconeogenesis in mice independently of the LKB1/AMPK pathway via a decrease in hepatic energy state. J Clin Invest 120: 2267-2270.
15. Hardie DG. (2006). Neither LKB1 nor AMPK are the direct targets of metformin. Gastroenterology 131: 973. (Pubitemid 44307086)
16. Hardie DG. (2007). AMP-activated/SNF1 protein kinases: conserved guardians of cellular energy. Nat Rev Mol Cell Biol 8: 774-785. (Pubitemid 47462132)
17. Hosono K, Endo H, Takahashi H, Sugiyama M, Sakai E, Uchiyama T et al. (2007). Metformin suppresses colorectal aberrant crypt foci in a short-term clinical trial. Can Prev Res 3: 1077-1083.
18. Huang X, Wullschleger S, Shpiro N, McGuire VA, Sakamoto K, Woods YL et al. (2008). Important role of the LKB1-AMPK pathway in suppressing tumourigenesis in PTEN deficient mice. Biochem J 412: 211-221. (Pubitemid 351758227)
19. Ji H, Ramsey MR, Hayes DN, Fan C, McNamara K, Kozlowski P et al. (2007). LKB1 modulates lung cancer differentiation and metastasis. Nature 448: 807-810. (Pubitemid 47266337)
20. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y et al. (2005). AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol Cell 18: 283-293. (Pubitemid 41350534)
21. Kalaany NY, Sabatini DM. (2009). Tumours with PI3K activation are resistant to dietary restriction. Nature 458: 725-731.
22. Kalender A, Selvaraj A, Kim SY, Gulati P, Brule S, Viollet B et al. (2010). Metformin, independent of AMPK, inhibits mTORC1 in a rag GTPase-dependent manner. Cell Metab 11: 390-401.
23. Kroemer G, Pouyssegur J. (2008). Tumor cell metabolism: cancer's Achilles' heel. Cancer Cell 13: 472-482. (Pubitemid 351766797)
24. Landman GW, Kleefstra N, van Hateren KJ, Groenier KH, Gans RO, Bilo HJ. (2010). Metformin associated with lower cancer mortality in type 2 diabetes: ZODIAC-16. Diabetes Care 33: 322-326.
25. Larsson SC, Mantzoros CS, Wolk A. (2007). Diabetes mellitus and risk of breast cancer: a meta-analysis. Int J Cancer 121: 856-862. (Pubitemid 47106217)
26. Larsson SC, Orsini N, Wolk A. (2005). Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97: 1679-1687. (Pubitemid 41672234)
27. Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. (2009). New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care 32: 1620-1625.
28. Liu B, Fan Z, Edgerton SM, Deng XS, Alimova IN, Lind SE et al. (2009). Metformin induces unique biological and molecular responses in triple negative breast cancer cells. Cell Cycle 8: 2031-2040.
29. Memmott RM, Mercado JR, Maier CR, Kawabata S, Fox SD, Dennis PA. (2010). Metformin prevents tobacco carcinogen-induced lung tumorigenesis. Can Prev Res 3: 1066-1076.
30. Novosyadlyy R, Lann DE, Vijayakumar A, Rowzee A, Lazzarino DA, Fierz Y et al. (2010). Insulin-mediated acceleration of breast cancer development and progression in a nonobese model of type 2 diabetes. Cancer Res 70: 741-751.
31. Owen MR, Doran E, Halestrap AP. (2000). Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J 348(Part 3): 607-614. (Pubitemid 30410251)
32. Pollak M. (2008). Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 8: 915-928.
33. Pollak M. (2009). Do cancer cells care if their host is hungry? Cell Metab 9: 401-403.
34. Pollak M. (2010). Metformin and other biguanides in oncology: advancing the research agenda. Can Prev Res 3: 1060-1065.
35. Russell III RR, Li J, Coven DL, Pypaert M, Zechner C, Palmeri M et al. (2004). AMP-activated protein kinase mediates ischemic glucose uptake and prevents postischemic cardiac dysfunction, apoptosis, and injury. J Clin Invest 114: 495-503. (Pubitemid 39572099)
36. Sakamoto K, McCarthy A, Smith D, Green KA, Grahame HD, Ashworth A et al. (2005). Deficiency of LKB1 in skeletal muscle prevents AMPK activation and glucose uptake during contraction. EMBO J 24: 1810-1820. (Pubitemid 40769500)
37. Sanchez-Cespedes M, Parrella P, Esteller M, Nomoto S, Trink B, Engles JM et al. (2002). Inactivation of LKB1/STK11 is a common event in adenocarcinomas of the lung. Cancer Res 62: 3659-3662. (Pubitemid 34728843)
38. Shackelford DB, Shaw RJ. (2009). The LKB1-AMPK pathway: metabolism and growth control in tumour suppression. Nat Rev Cancer 9: 563-575.
39. Shaw RJ, Kosmatka M, Bardeesy N, Hurley RL, Witters LA, Depinho RA et al. (2004). The tumor suppressor LKB1 kinase directly activates AMP-activated kinase and regulates apoptosis in response to energy stress. Proc Natl Acad Sci USA 101: 3329-3335. (Pubitemid 38338195)
40. Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA et al. (2005). The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310: 1642-1646. (Pubitemid 41780780)
41. Tennant DA, Duran RV, Gottlieb E. (2010). Targeting metabolic transformation for cancer therapy. Nat Rev Cancer 10: 267-277.
42. Tomimoto A, Endo H, Sugiyama M, Fujisawa T, Hosono K, Takahashi H et al. (2008). Metformin suppresses intestinal polyp growth in ApcMin/+ mice. Cancer Sci 99: 2136-2141.
43. Van Lier MG, Wagner A, Mathus-Vliegen EM, Kuipers EJ, Steyerberg EW, Van Leerdam ME. (2010). High cancer risk in Peutz-Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol 105: 1258-1264.
44. Venkateswaran V, Haddad AQ, Fleshner NE, Fan R, Sugar LM, Nam R et al. (2007). Association of diet-induced hyperinsulinemia with accelerated growth of prostate cancer (LNCaP) xenografts. J Natl Cancer Inst 99: 1793-1800. (Pubitemid 351767208)
45. Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R. (2009). Diabetes and cancer. Endocr Relat Cancer 16: 1103-1123.
46. Wingo SN, Gallardo TD, Akbay EA, Liang MC, Contreras CM, Boren T et al. (2009). Somatic LKB1 mutations promote cervical cancer progression. PLoS One 4: e5137.
47. Zakikhani M, Dowling R, Fantus IG, Sonenberg N, Pollak M. (2006). Metformin is an AMP kinase-dependent growth inhibitor for breast cancer cells. Cancer Res 66: 10269-10273. (Pubitemid 44799743)
48. Zakikhani M, Dowling RJ, Sonenberg N, Pollak MN. (2008). The effects of adiponectin and metformin on prostate and colon neoplasia involve activation of AMP-activated protein kinase. Cancer Prev Res (Phila, PA) 1: 369-375.